Ideaya Biosciences Ownership
| IDYA Stock | USD 27.36 0.37 1.37% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 78 M | Current Value 86.2 M | Avarage Shares Outstanding 37.5 M | Quarterly Volatility 21 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Ideaya |
Ideaya Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The book value of Ideaya Biosciences was currently reported as 13.67. The company recorded a loss per share of 2.33. Ideaya Biosciences had not issued any dividends in recent years. IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Ideaya Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 91 people. To learn more about Ideaya Biosciences call the company at 650 443 6209 or check out https://www.ideayabio.com.Besides selling stocks to institutional investors, Ideaya Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Ideaya Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Ideaya Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Ideaya Biosciences Quarterly Liabilities And Stockholders Equity |
|
Ideaya Biosciences Insider Trades History
Only 1.03% of Ideaya Biosciences are currently held by insiders. Unlike Ideaya Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Ideaya Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Ideaya Biosciences' insider trades
Ideaya Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ideaya Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ideaya Biosciences backward and forwards among themselves. Ideaya Biosciences' institutional investor refers to the entity that pools money to purchase Ideaya Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Adage Capital Partners Gp Llc | 2024-06-30 | 2.1 M | Geode Capital Management, Llc | 2024-09-30 | 1.9 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.6 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.6 M | Bvf Inc | 2024-09-30 | 1.4 M | Avidity Partners Management Lp | 2024-09-30 | 1.4 M | Ra Capital Management, Llc | 2024-09-30 | 1.3 M | Fiera Capital Corporation | 2024-06-30 | 1.3 M | Sofinnova Ventures | 2024-06-30 | 1.2 M | Fmr Inc | 2024-09-30 | 12.6 M | Blackrock Inc | 2024-06-30 | 6.8 M |
Ideaya Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ideaya Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ideaya Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ideaya Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ideaya Biosciences Outstanding Bonds
Ideaya Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ideaya Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ideaya bonds can be classified according to their maturity, which is the date when Ideaya Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| IEX 2625 15 JUN 31 Corp BondUS45167RAH75 | View | |
| US45167RAG92 Corp BondUS45167RAG92 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Ideaya Biosciences Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 27th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 10th of July 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ideaya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ideaya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ideaya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ideaya Biosciences Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ideaya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ideaya Biosciences. If investors know Ideaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ideaya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.33) | Revenue Per Share 0.051 | Quarterly Revenue Growth (0.03) | Return On Assets (0.16) | Return On Equity (0.21) |
The market value of Ideaya Biosciences is measured differently than its book value, which is the value of Ideaya that is recorded on the company's balance sheet. Investors also form their own opinion of Ideaya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ideaya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ideaya Biosciences' market value can be influenced by many factors that don't directly affect Ideaya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ideaya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ideaya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ideaya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.